NDAINJECTIONINJECTABLE
Approved
Jun 2008
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
6
Data completeness
5/8 — Partial
VELETRI (epoprostenol) by Johnson & Johnson is 2 major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. First approved in 2008.
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELETRI (epoprostenol) is a prostacycline vasodilator administered by injection that directly dilates pulmonary and systemic arterial beds while inhibiting platelet aggregation. It is indicated for pulmonary arterial hypertension (PAH) and related conditions requiring potent vasodilation and antiplatelet effects. The drug represents a cornerstone therapy in the PAH treatment armamentarium, though patient burden from continuous IV infusion administration limits adoption.
$0.76MPart D
LOE Approaching4mo to LOEWith patent expiration imminent in March 2027 (0.5 years remaining), the brand team faces rapid LOE transition; commercial headcount and investment are likely already declining or pivoting to lifecycle management and generic defense strategies.
Mechanism of Action
2 major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation.
Pharmacologic Class:
Prostacycline Vasodilator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)
Started Feb 2026
66 enrolled
Frostbite
VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB
Started Aug 2017
17 enrolled
Pulmonary Hypertension
Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)
Started Nov 2011
16 enrolled
Hypertension, Pulmonary
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
Started Sep 2006
10 enrolled
Pulmonary Hypertension
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Started Jul 2003
267 enrolled
Pulmonary Hypertension
Worked on VELETRI at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.